<DOC>
	<DOCNO>NCT02060266</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate absorption , metabolism excretion single subcutaneous dose [ 3H ] -semaglutide healthy male subject .</brief_summary>
	<brief_title>Trial Investigating Absorption , Metabolism Excretion After Single Subcutaneous Dose 3H-Semaglutide Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male subject , base assessment medical history , physical examination , ECG ( electrocardiogram ) vital sign , determine investigator Age 4564 year ( inclusive ) time sign inform consent Body mass index ( BMI ) 20 30 kg/m^2 ( inclusive ) Donation blood plasma past month excess 100 mL within 3 month precede screening , surgery trauma 100 mL blood loss within 3 month precede screen Use prescription nonprescription systemic topical medicinal product ( except routine vitamin , acetylsalicylic acid paracetamol ) within 3 week ( within 5 halflives medicinal product , whichever long ) prior visit 2 , Day 1 History drug/chemical substance abuse within 1 year screening , positive result urine drug test History alcohol abuse within 1 year screening , positive result alcohol urine test , consumption 21 unit alcohol weekly ( one unit alcohol equal 250 mL beer lager , one glass ( 120 mL ) wine , 20 mL spirit ) Smoking use nicotine ( include nicotine patch , gum , etc ) last 3 month prior screen positive nicotine test</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>